A pathway to developing and testing quality measures aimed at improving adult vaccination rates in the United States

• Published in: Vaccine 2019-02, Vol.37 (10), p.1277-1283
• Main Authors: Shen, Angela K., Groom, Amy V., Leach, Diane L., Bridges, Carolyn B., Tsai, Alice Y., Tan, Litjen
• Format: Article
• Language: English
• Subjects: Adult vaccination; Adults; Composite measurement; Data collection; Diphtheria; Disease control; HEDIS; Herpes zoster; Immunization; Incentives; Influenza; Influenza, Tdap, Td, Pneumococcal, Zoster vaccines; Medicare; Performance measurement; Pertussis; Pregnancy; Public health; Public private partnerships; Quality measurement; Tetanus; Vaccines; Womens health
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2019.01.044

Despite recommendations for vaccinating adults and widespread availability of immunization services (e.g., pharmacy venues, workplace wellness clinics), vaccination rates in the United States remain low. The U.S. National Adult Immunization Plan identified the development of quality measures as a priority and key strategy to address low adult vaccination coverage rates. The use of quality measures can provide incentives for increased utilization of preventive services. To address the lack of adult immunization measures, the National Adult and Influenza Immunization Summit, a coalition of adult immunization partners led by the Immunization Action Coalition, Centers for Disease Control and Prevention, and National Vaccine Program Office, spearheaded efforts to (1) identify gaps and priorities in adult immunization quality performance measurement; (2) explore feasibility of data collection on adult immunizations through pilot testing and engaging stakeholders; and (3) develop and test quality measure specifications. This paper outlines the process by which a public-private partnership drove the development of two adult immunization performance measures—an adult immunization status measure for influenza, tetanus and diphtheria (Td) and/or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), herpes zoster and pneumococcal vaccines, and a prenatal immunization status measure for influenza and Tdap vaccinations in pregnant women. These measures have recently been added to the 2019 Healthcare Effectiveness Data and Information Set (HEDIS®), a widely used set of performance measures reportable by private health plans.